Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies Nov 20, 2024 08:00AM
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio Nov 13, 2024 08:00AM
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors Oct 3, 2024 08:00AM
Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World Jul 25, 2024 08:00AM
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Apr 8, 2024 08:00AM
View Older Stories

Mar 6, 2024 07:00AM Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
Jan 5, 2024 10:00AM Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
Dec 4, 2023 04:00PM Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Nov 13, 2023 07:00AM Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
Nov 7, 2023 04:00PM Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
Nov 1, 2023 10:30AM Flagship Pioneering Launches Pioneering Intelligence
Oct 31, 2023 07:00AM Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
Oct 16, 2023 07:01AM Omega Therapeutics (OMGA) Presents New Preclinical Data Supporting the Potential of OTX-2101
Oct 16, 2023 07:00AM Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
Oct 11, 2023 04:00PM Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
Oct 4, 2023 04:00PM Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 26, 2023 07:01AM Omega Therapeutics (OMGA) Reports Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial
Sep 26, 2023 07:00AM Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial
Sep 25, 2023 04:00PM Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
Sep 21, 2023 04:00PM Omega Therapeutics to Participate in Two Upcoming Investor Conferences
Aug 29, 2023 09:00AM Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
Aug 29, 2023 07:01AM Omega Therapeutics (OMGA) Announces Board Changes
Aug 29, 2023 07:00AM Omega Therapeutics Announces Updates to its Board of Directors
Aug 3, 2023 04:00PM Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Jul 12, 2023 07:04AM Omega Therapeutics (OMGA) Appoints Chris Schade to its Board
Jul 12, 2023 07:00AM Omega Therapeutics Appoints Chris Schade to its Board of Directors
Jun 1, 2023 07:00AM Omega Therapeutics to Participate in Two Upcoming Investor Conferences
May 31, 2023 07:00AM Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting
May 16, 2023 06:00AM Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
May 4, 2023 07:00AM Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Apr 27, 2023 07:00AM Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting
Apr 27, 2023 07:00AM Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting
Mar 30, 2023 07:02AM Omega Therapeutics (OMGA) Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab
Mar 30, 2023 07:00AM Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
Mar 30, 2023 07:00AM Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
Mar 1, 2023 07:00AM Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 1, 2023 07:00AM Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Jan 17, 2023 07:00AM Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Jan 17, 2023 07:00AM Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Dec 8, 2022 08:00AM KSQ Appoints Mahesh Karande to its Board of Directors
Nov 17, 2022 07:00AM Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 15, 2022 07:00AM Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work
Nov 8, 2022 07:00AM Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 3, 2022 07:00AM Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
Nov 2, 2022 07:01AM Omega Therapeutics (OMGA) Granted Orphan Drug Designation for OTX-2002
Nov 2, 2022 07:00AM Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma
Oct 27, 2022 07:00AM Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
Oct 12, 2022 07:00AM Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer
Sep 26, 2022 07:00AM Omega Therapeutics to Participate in Two Upcoming Investor Conferences
Sep 6, 2022 07:00AM Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 07:00AM Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
Aug 16, 2022 07:00AM Senda Biosciences Announces Close of $123 Million Series C Financing
Aug 4, 2022 07:00AM Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Aug 3, 2022 07:00AM Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Jul 14, 2022 04:05PM Omega Therapeutics (OMGA) Announces FDA Clearance of IND for OTX-2002
View Older Stories